ALK and non-Hodgkin lymphoma: This was followed in-tandem by a phase I study in adults with ALK-positive NHL (ALK-positive ALCL: n = 9, ALK-positive diffuse large B-cell lymphoma: n = 2) who received crizotinib monotherapy.